Puma Biotechnology
PBYI
104 hedge funds and large institutions have $86.1M invested in Puma Biotechnology in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 26 increasing their positions, 41 reducing their positions, and 17 closing their positions.
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
2% more funds holding
Funds holding: 102 → 104 (+2)
1.87% less ownership
Funds ownership: 74.27% → 72.41% (-1.9%)
7% less capital invested
Capital invested by funds: $92.2M → $86.1M (-$6.07M)
37% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 41
63% less call options, than puts
Call options by funds: $211K | Put options by funds: $573K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$5.04M |
| 2 |
ACM
Athyrium Capital Management
New York
|
+$4.64M |
| 3 |
EP
Eversept Partners
New York
|
+$793K |
| 4 |
D.E. Shaw & Co
New York
|
+$698K |
| 5 |
Millennium Management
New York
|
+$528K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.77M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.3M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.82M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.21M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$916K |
PBYI Hedge Fund Activity: Q1 2022 in Review
104 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2022, worth a combined $86.1M — down 6.6% from $92.2M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PBYI positions and 17 closed out — a net gain of 3 holders — while 26 added to existing stakes and 41 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $5.04M. The largest seller was Goldman Sachs, cutting an estimated $4.77M.
- 104 institutional investors held Puma Biotechnology (PBYI) as of Q1 2022, up from 102 in Q4 2021.
- Funds reported $86.1M of Puma Biotechnology stock for Q1 2022, down 6.6% quarter-over-quarter.
- 20 funds opened new Puma Biotechnology positions in Q1 2022 and 17 closed out, a net change of +3 holders.
- The largest Puma Biotechnology buyer in Q1 2022 was Camber Capital Management, an estimated $5.04M added.
- The largest Puma Biotechnology seller in Q1 2022 was Goldman Sachs, an estimated $4.77M sold.
Based on aggregated 13F filings for Q1 2022.